SPCX Research Note — Earnings Meets Supply
SpaceX operating progress meets SPCX’s unresolved post-IPO tape as first earnings and a large August share release test public-market demand.
Research Notes
WST Research Note — Growth Meets a Credibility Test
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
Why Two Similar Markets Rarely Deserve Equal Weight
Correlated instruments travel together until they separate, and the moment of separation is usually more informative than either one on its own. This note describes how the CAMS desk reads that gap.
MOH Research Note — The Beat Masks Strain
Molina’s earnings beat and raised outlook face a harder test from weak premium revenue, declining membership and sharply compressed margins.
ASML Research Note — Monopoly Quality Needs Confirmation
ASML’s monopoly remains intact, but bookings evidence and China-policy exposure must confirm the next phase of the equipment cycle.
MS Research Note — Franchise Quality Meets an Evidence Gap
Morgan Stanley’s improving returns support its franchise, while relative weakness and an unresolved wealth-margin bridge raise the evidence bar.
UNH Research Note — Better Headlines, Unresolved Costs
UnitedHealth’s better quarter did not settle the medical-cost debate as the shares reversed sharply despite broader health-care leadership.
LLY Research Note — Franchise Strength Meets Valuation Risk
Lilly’s incretin franchise remains powerful, while valuation, policy and access risks make the August 5 evidence window unusually important.
VRT Research Note — Strength Meets Event Risk
Vertiv’s backlog and AI infrastructure demand remain firm, while weak intermediate structure makes the July 29 evidence window unusually important.
NVDA Research Note — Quality Meets a Narrow Timing Edge
NVIDIA’s operating strength supports the long-term thesis, while customer concentration and a flat market structure demand fresh confirmation.